We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.9B
AUM Growth
+$430M
Cap. Flow
-$2.03B
Cap. Flow %
-9.27%
Top 10 Hldgs %
51.69%
Holding
190
New
27
Increased
30
Reduced
39
Closed
32

Top Buys

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$731M
2
HES
Hess
HES
+$436M
3
NDAQ icon
Nasdaq
NDAQ
+$341M
4
SPLK
Splunk Inc
SPLK
+$157M
5
UTHR icon
United Therapeutics
UTHR
+$110M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$1.9B
2
VMW
VMware, Inc
VMW
+$915M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$770M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$482M
5
AON icon
Aon
AON
+$216M

Sector Composition

Rank Sector Weight
1 Healthcare 27.49%
2 Technology 11.1%
3 Financials 9.67%
4 Industrials 6.16%
5 Communication Services 5.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMED
51
DELISTED
Amedisys
AMED
$65.2M 0.3%
686,000
+262,000
+62% +$24.5M
CTLT
52
DELISTED
CATALENT, INC.
CTLT
$63.5M 0.29%
+1,413,000
New +$57.2M
PACB icon
53
Pacific Biosciences
PACB
$420M
$60.7M 0.28%
6,191,370
-4,032,750
-39% -$33M
HUM icon
54
Humana
HUM
$45.5B
$55.6M 0.25%
121,344
-243,117
-67% -$120M
BABA icon
55
Alibaba
BABA
$286B
$41.5M 0.19%
535,000
-327,233
-38% -$26.1M
PCG icon
56
PG&E
PCG
$38.8B
$41M 0.19%
2,271,642
-1,950,000
-46% -$32.9M
COR icon
57
Cencora
COR
$60.7B
$34.7M 0.16%
+169,000
New +$33M
BHVN icon
58
Biohaven
BHVN
$2.09B
$32.1M 0.15%
750,000
– –
SVRA icon
59
Savara
SVRA
$1.15B
$29.4M 0.13%
6,255,406
-4,652,680
-43% -$17.8M
THC icon
60
Tenet Healthcare
THC
$22.6B
$28.3M 0.13%
374,842
-655,158
-64% -$41.5M
IMGN
61
DELISTED
Immunogen Inc
IMGN
$25M 0.11%
+842,000
New +$16.8M
CERE
62
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$24.1M 0.11%
+567,321
New +$16.3M
VRTX icon
63
Vertex Pharmaceuticals
VRTX
$139B
$22.4M 0.1%
55,000
-147,000
-73% -$54.3M
OPCH icon
64
Option Care Health
OPCH
$3.55B
$19.1M 0.09%
567,800
-294,200
-34% -$9.04M
ENTA icon
65
Enanta Pharmaceuticals
ENTA
$392M
$19.1M 0.09%
2,025,000
+150,000
+8% +$1.4M
ZYME icon
66
Zymeworks
ZYME
$2.05B
$18.2M 0.08%
1,756,000
-244,000
-12% -$1.94M
TAL icon
67
TAL Education Group
TAL
$6.28B
$17.2M 0.08%
1,365,000
– –
SIMO icon
68
Silicon Motion
SIMO
$8.76B
$15.1M 0.07%
246,500
-798,500
-76% -$45.7M
IMVT icon
69
Immunovant
IMVT
$9.16B
$14.4M 0.07%
341,000
-163,000
-32% -$6M
LNTH icon
70
Lantheus
LNTH
$6.53B
$13.2M 0.06%
213,327
-1,385,173
-87% -$93.9M
VYGR icon
71
Voyager Therapeutics
VYGR
$209M
$10.9M 0.05%
1,292,000
– –
SCRM
72
DELISTED
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
$10.6M 0.05%
1,000,000
– –
RIO icon
73
Rio Tinto
RIO
$171B
$10.2M 0.05%
137,500
– –
TVTX icon
74
Travere Therapeutics
TVTX
$6.19B
$9.84M 0.05%
1,094,000
+822,483
+303% +$5.99M
NBIX icon
75
Neurocrine Biosciences
NBIX
$15.5B
$9.54M 0.04%
72,398
-375,602
-84% -$43.2M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2023 Portfolio in Review

As of Q4 2023, Thomas Steyer held 190 positions worth $21.9B, up 2% from $21.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Thomas Steyer withdrew a net $2.03B in Q4 2023, closing 32 positions and reducing 39 holdings. Its most notable exit was Activision Blizzard, an estimated $1.9B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 31% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Pioneer Natural Resource Co. worth $702M.

  • Thomas Steyer's largest Q4 2023 buy was Pioneer Natural Resource Co.: 3,120,000 shares worth $702M.
  • Thomas Steyer added most to Nasdaq in Q4 2023, an estimated $341M increase.
  • Thomas Steyer's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $145M.
  • Thomas Steyer fully exited Activision Blizzard in Q4 2023, selling an estimated $1.9B.
  • Thomas Steyer's ten largest holdings make up 52% of its $21.9B portfolio in Q4 2023.
  • Thomas Steyer opened 27 new positions and closed 32 in Q4 2023.
  • Thomas Steyer's portfolio value rose 2% quarter-over-quarter to $21.9B.

Based on Farallon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.